Abstract: Objective To observe and compare the efficacy of timolol eye drops in sequential treatment of acute angle-closure crisis. Methods In this prospective, randomized, double-blind case-control study, patients diagnosed with acute angle-closure crisis(AACC)at the Affiliated Hospital of Hebei University from April 2021 to October 2023 were continuously enrolled. The patient data were collected and randomly divided into timolol group(group A)and placebo group(group B). All patients were sequentially treated with drug therapy, anterior chamber paracentesis and argon laser peripheral iridoplasty. The primary outcomes were decreased intraocular pressure, success rate, and treatment time. Results At 2 hours, 4 hours and 6 hours after the start of treatment, the reduction of intraocular pressure(IOP)in group A were(13.87±13.85)mmHg(1 mmHg=0.133 kPa),(28.42±12.87)mmHg and(35.69±8.51)mmHg respectively, the number of controlled eyes were 23 eyes(29.87%), 51 eyes(66.23%)and 71 eyes(92.20%)respectively. The reduction of IOP in group B were(15.88±14.95)mmHg,(28.17±13.63)mmHg,(33.90±13.59)mmHg respectively, the number of controlled eyes were 30 eyes(36.59%), 58 eyes(70.73%)and 75 eyes(91.46%)respectively. Among patients whose crisis were relieved, the times for AACC relief were(3.29±1.31)hours in group A and(3.38±1.34)hours in group B. There were no significant differences in IOP reduction, numbers of eyes remission and times for AACC relief between the two groups at each point of sequential treatment(P>0.05 ). Conclusion In the sequential treatment of AACC, timolol is not helpful to improve the success rate of treatment.

Key words: primary angleclosure glaucoma, acute angle-closure crisis, timolol eye drops, sequential therapy, case-control study